Clinical trial
New Drugs in the Treatment of Mood Disorders
NCT00001482 · National Institute of Mental Health (NIMH), NIH · Completed
Key facts
| NCT number | NCT00001482 |
|---|---|
| Title | New Drugs in the Treatment of Mood Disorders |
| Official title | Evaluation of Lamotrigine (Lamictal® (Registered Trademark)) Monotherapy and Gabapentin (Neurontin® (Registered Trademark)) Monotherapy in the Treatment of Mood Disorders |
| Lead sponsor | National Institute of Mental Health (NIMH), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anxiety Disorder, Mood Disorder, Psychotic Disorder |
| Intervention type | Drug |
| Interventions | Lamotrigine (Lamictal® (Registered Trademark), Gabapentin (Neurontin® (Registered Trademark)) |
| Enrollment | 60 |
| Start date | May 1, 1995 |
| Completion | May 1, 2001 |
| First posted | Dec 10, 2002 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: